International Acupuncture and Moxibustion Innovation Institute, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, 100029, China.
School of Acupuncture-Moxibustion and Tuina, Hebei University of Chinese Medicine, Shijiazhuang, 050299, China.
Trials. 2022 Aug 26;23(1):711. doi: 10.1186/s13063-022-06639-5.
Diarrhea-predominant irritable bowel syndrome (IBS-D) is the most common subtype of IBS. Acupuncture is commonly used to treat IBS-D, but its effect is uncertain because of the poor quality of prior studies. This trial aims to evaluate the efficacy and safety of acupuncture treatment for IBS-D through comparisons with sham acupuncture.
METHODS/DESIGN: This is a large-scale, multi-center, randomized, two-arm interventional clinical trial. Participants will take part in a total of 20 weeks of study, which contained 3 phases: 2-week screening, 6-week treatment, and 12-week follow-up. Based on the composite response rate of the primary endpoint in our pilot study (a sham acupuncture response rate of 27% and a true acupuncture of approximately 45%), 280 randomly allocated participants were planned. Eligible participants will be randomly assigned to the true acupuncture group and sham acupuncture group according to a ratio of 1:1, and a total of 15 sessions of treatment overall 6-week treatment period will be brought. The primary endpoint is a composite response rate at week 6, and the responder is defined as who responses in both abdominal pain intensity and stool consistency. Furthermore, composite response rates at other weeks, IBS Symptom Severity Scale, IBS Quality of Life, Adequate Relief scale, and individual IBS symptoms (abdominal pain, bloating, stool frequency) are chosen as secondary endpoints.
This trial may provide high-quality evidence for the efficacy and safety of acupuncture in the treatment of IBS-D. The results of this study will be published in peer-reviewed journals.
Chinese Clinical Trial Registry: ChiCTR2100044762. Registered on 26 March 2021.
腹泻型肠易激综合征(IBS-D)是最常见的 IBS 亚型。针灸常用于治疗 IBS-D,但由于先前研究质量较差,其效果不确定。本试验旨在通过与假针灸比较评估针灸治疗 IBS-D 的疗效和安全性。
方法/设计:这是一项大规模、多中心、随机、双臂干预性临床试验。参与者将参加总共 20 周的研究,包括 3 个阶段:2 周筛选期、6 周治疗期和 12 周随访期。根据我们的预试验的主要终点综合反应率(假针灸反应率为 27%,真针灸约为 45%),计划了 280 名随机分配的参与者。符合条件的参与者将根据 1:1 的比例随机分配到真针灸组和假针灸组,在 6 周治疗期间总共进行 15 次治疗。主要终点是第 6 周的综合反应率,应答者定义为在腹痛强度和粪便稠度两方面均有反应的患者。此外,选择综合反应率在其他周、IBS 症状严重程度量表、IBS 生活质量、充分缓解量表以及个体 IBS 症状(腹痛、腹胀、排便频率)作为次要终点。
本试验可能为针灸治疗 IBS-D 的疗效和安全性提供高质量证据。研究结果将发表在同行评议的期刊上。
中国临床试验注册中心:ChiCTR2100044762。注册于 2021 年 3 月 26 日。